What is the current stock price of Agilent Technologies, Inc. (A)?

As of the latest market data, Agilent Technologies, Inc. (A) is trading at $115.06. The stock has seen a loss of -0.29% today.

Does Agilent Technologies, Inc. (A) pay a dividend?

Based on current data, Agilent Technologies, Inc. does not have a confirmed active dividend policy.

What is the market cap of Agilent Technologies, Inc.?

The current market capitalization of Agilent Technologies, Inc. (A) is approximately unavailable.

A

Agilent Technologies, Inc.·Healthcare

115.06

0.29%(−0.33)

Close Price

116.28

1.06%(+1.22)

After Hours

Last Updated: — ET

52W L: $98.8652W H: $160.27

A NEWS

defenseworld.net

1d ago

Agilent Technologies, Inc. $A Shares Bought by CCLA Investment Management

CCLA Investment Management grew its holdings in shares of Agilent Technologies, Inc. (NYSE: A) by 1.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,047,488 shares of the medical research company's stock after purchasing an additional 19,518 shares

defenseworld.net

6d ago

Agilent Technologies, Inc. (NYSE:A) Receives Average Rating of “Moderate Buy” from Brokerages

Agilent Technologies, Inc. (NYSE: A - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen research firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to

defenseworld.net

6d ago

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $1.70 Million Position in Agilent Technologies, Inc. $A

Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Agilent Technologies, Inc. (NYSE: A) by 288.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,463 shares of the medical research company's stock after acquiring an additional 9,258

businesswire.com

Apr 1

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea.

zacks.com

Mar 27

Why Is Agilent (A) Down 6.2% Since Last Earnings Report?

Agilent (A) reported earnings 30 days ago. What's next for the stock?

businesswire.com

Mar 26

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica.

Company Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

17,900

IPO Date

1999-11-18

Beta

1.30

Websitewww.agilent.com↗